Dr Keith Michael Gottesdiener, Director and CEO & President, exercised options for 33,072 shares in Rhythm Pharmaceuticals (RYTM) for $151,800 on Jan 08,...
Rhythm Pharmaceuticals' (RYTM) average rating among analysts is a buy, with an average price target of $39. Price: 21.42, Change: -0.92, Percent Change:...
Rhythm Pharmaceuticals (RYTM) said on Monday Keith Gottesdiener plans to step down as CEO following the completion of its new drug application of...
Todd Foley, Director, on Dec 11, 2019, sold 17,362 shares in Rhythm Pharmaceuticals (RYTM) for $435,992. Foley, subsequent to the transactions disclosed...
| Address | 222 Berkeley Street Boston, Massachusetts 02116 |
| Phone | +1.857.264.4280 |
| Number of Employees | 54 |
| Recent SEC Filing | 01/28/2020 SC 13G |
| President, Chief Executive Officer & Director | Keith M. Gottesdiener |
| Chief Financial Officer & Treasurer | Hunter C. Smith |
| Chief Medical Officer | Murray W. Stewart |
| Chief Commercial Officer | Nithya Desikan |
| Price Open | $17.67 |
| Previous Close | $17.55 |
| 52 Week Range | $17.26 - 31.94 |
| Market Capitalization | $801.6 M |
| Shares Outstanding | 43.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/13/2020 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$3.87 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -66.86% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
